Abstracts tagged "anti-TNF therapy"

Abstract Number: 571 • 2019 ACR/ARP Annual Meeting
Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry
Jina Yeo¹, Mi Ryoung Seo ¹, Hee Jung Ryu ¹, Hyo-Jin Choi ¹ and Han Joo Baek ¹, ¹Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…
Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Burkhard Moeller¹, Eleftherios Papagiannoulis ², Lisa Christ ³, Adrian Ciurea ⁴, Thomas Hugle ⁵, Ruediger B. Mueller ⁶, Michael J. Nissen ⁷, Almut Scherer ⁸, Godehard Scholz ³, Peter M. Villiger ¹ and Nikhil Yawalkar ³, ¹University Hospital Bern, Bern, Switzerland, ²SCQM Zurich, Zurich, Switzerland, ³Inselspital-University Hospital Bern, Bern, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵University Hospital Lausanne, Lausanne, Switzerland, ⁶Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ⁷University Hospital Geneva, Geneva, Switzerland, ⁸SCQM Foundation, Zürich, Switzerland
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
Abstract Number: 581 • 2019 ACR/ARP Annual Meeting
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Jeong Seok Lee¹, Eunyoung Lee ², Ji Yong Choi ³, Yeong-Wook Song ⁴, Eui-Cheol Shin ¹ and Eun Young Lee ², ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Seoul, Republic of Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…
Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
René-Marc Flipo ¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Jean-Marie Fayette ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Emma Hernlund ¹, Johan Klint ¹, Axel Svedbom ¹, Johan Dalén ¹, Christopher Black ² and Amy Puenpatom², ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ
Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…
Abstract Number: 619 • 2019 ACR/ARP Annual Meeting
Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty
Rachael Stovall¹, Christine Peloquin ², David Felson ³, Tuhina Neogi ² and Maureen Dubreuil ⁴, ¹Boston Medical Center, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Department of Rheumatology, Boston, ⁴Boston University School of Medicine, Boston
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory arthritis that predominantly affects the axial skeleton, but commonly affects peripheral joints as well. Peripheral joint involvement often…
Abstract Number: 1512 • 2019 ACR/ARP Annual Meeting
Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results
Gozde Kubra Yardımcı ¹, Bayram Farisoğulları ¹, Alper Sarı ¹, Levent Kilic ², Berkan Armagan ³, Emre Bilgin ¹, Ertugrul Cagri Bolek ¹, Omer Karadag ⁴, Ali Akdoğan ¹, Şule Apras Bilgen ², Ali İhsan Ertenli ¹, Sedat Kiraz ² and Umut Kalyoncu⁵, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Enteropathic spondylitis (eSpA) is younger brother of spondyloarthritis, and the retention rate of biological DMARD in eSpA was not yet clear. The objective of this study was to…
Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson¹, Olafur Palsson ², Mar Kristjansson ³, Petur S Gunnarsson ⁴, Gerdur Grondal ⁵, Bjorn Gudbjornsson ⁶ and Thorvardur J Love ⁷, ¹Department of Medicine, Landspitali, Reykjavík, Iceland, ²Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, ³Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, ⁴Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, ⁵Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
Abstract Number: 933 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Bon San Koo¹, Ji Seon Oh ², Seo Young Park ³, Ga Young Ahn ⁴, Seunghun Lee ⁵, Kyung Bin Joo ⁶ and Tae-Hwan Kim ⁷, ¹Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea, ³Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Korea University Guro Hospital, Seoul, Republic of Korea, ⁵Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁶Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…
Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Matthew Thomas ¹, Gavin Shaddick ², Rachel Charlton ¹, Charlotte Cavill ³, Richard Holland ⁴, Florenzo Iannone ⁵, Giovanni Lapadula ⁶, Simona Lapriore ⁵, Jakub Závada ⁷, Michal Uher ⁸, Karel Pavelka ⁹, Lenka Szczukova ¹⁰, Prodromos Sidiropolous ¹¹, Irini Flouri ¹¹, Burkhard Moeller ¹², Michael J. Nissen ¹³, Ruediger B. Mueller ¹⁴, Almut Scherer ¹⁵, Neil McHugh¹ and Alison Nightingale ¹, ¹University of Bath, Bath, United Kingdom, ²University of Exeter, Exeter, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵University of Bari, Bari, Italy, ⁶Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, ⁷Institute of Rheumatology, Prague, Prague, Czech Republic, ⁸Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁰Masaryk University, Brno, Czech Republic, ¹¹University of Crete, Crete, Greece, ¹²University Hospital Bern, Bern, Switzerland, ¹³University Hospital Geneva, Geneva, Switzerland, ¹⁴Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ¹⁵SCQM Foundation, Zürich, Switzerland
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
Abstract Number: 935 • 2019 ACR/ARP Annual Meeting
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Irene van der Horst-Bruinsma¹, Rianne van Bentum ¹, Frank D. Verbraak ¹, Thomas Rath ², James T. Rosenbaum ³, Maria Misterska-Skóra ⁴, Bengt Hoepken ⁵, Oscar Irvin-Sellers ⁶, Brenda VanLunen ⁷, Lars Bauer ⁵ and Martin Rudwaleit ⁸, ¹Amsterdam University Medical Center, Amsterdam, Netherlands, ²St Franziskus-Hospital, Münster, Germany, ³Devers Eye Institute and Oregon Health & Science University, Portland, OR, ⁴Wrocław Medical University, Wrocław, Poland, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, UK, Slough, United Kingdom, ⁷UCB Pharma, Raleigh, NC, ⁸Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…
Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Carlos Perez-Sanchez ³, Pilar Font ⁴, Alejandro Ibañez-Costa ¹, Maria Luque-Tevar ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Rafaela Ortega ¹, Alejandro Escudero ⁵, Laura Pérez-Sanchez ⁶, Jerusalem Calvo-Gutierrez ¹, Rocío Segura-Ruiz ⁷, Carlos Rodriguez Escalera ⁸, Dolores Ruiz-Montesinos ⁹, Carmen Romero Barco ¹⁰, N. Mena-Vazquez ¹¹, Julia Uceda Montañez ¹², Mª Dolores Toledo Coello ¹³, M Angeles Aguirre ¹⁴ and Eduardo Collantes-Estevez ⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁷Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁸Hospital Universitario de Jaén, Jaen, Spain, ⁹Hospital Virgen Macarena, Sevilla, ¹⁰Hospital Marítimo de Torremolinos, Málaga, Málaga, Spain, ¹¹HU Malaga., Malaga, ¹²Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹³Hospital Universitario de Jerez de la Frontera, Cádiz, Cádiz, Spain, ¹⁴IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…
Abstract Number: 936 • 2019 ACR/ARP Annual Meeting
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Jonathan Kay¹, Lianne Gensler ², Atul Deodhar ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Simone Auteri ⁶, Natasha de Peyrecave ⁷, Thomas Kumke ⁸, Bengt Hoepken ⁹, Lars Bauer ⁹ and Martin Rudwaleit ¹⁰, ¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany
Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…
Abstract Number: 2112 • 2019 ACR/ARP Annual Meeting
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Alazne Ruiz ¹, Juan Ramón De Dios ², Belen Alvarez ¹, Margarida Vasques Rocha ², Claudia Stoye ², Susana Gil ¹, Orlando Pompei Fernández ² and Jaime Calvo-Alen³, ¹Hospital Universitario Araba, Vitoria, Pais Vasco, Spain, ²Araba University Hospital, Vitoria, Pais Vasco, Spain, ³Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: To study frequency and associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods: All the medical records of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.